Freixa Román, Blanch Pedro, Ibernón Montse, Padró Jaume, Delso Javier, Sobrepera José Luis, Salas Elena, Dos Laura, Codinach Pere
Servicio de Cardiología, Hospital Creu Roja, Barcelona, Spain.
Rev Esp Cardiol. 2003 Jan;56(1):65-72. doi: 10.1016/s0300-8932(03)76823-7.
Few studies have attempted to investigate the clinical course or identify factors responsible for excessive anticoagulation in patients with heart disease.
To determine the incidence of excessive anticoagulation in outpatients with heart disease treated with acenocoumarol, analyze the factors related with over-anticoagulation, and identify bleeding complications.
This 7-month prospective observational study included consecutive outpatients anticoagulated with acenocoumarol. They were seen in an anticoagulation unit. The high INR group of 55 over-anticoagulated patients had at least one test with INR > 5. The control group of 49 patients had INR results strictly within therapeutic range.
A total of 3,683 INR determinations were made in 512 patients. Seventy-seven tests had an INR > 5 (a 2% overall incidence of high-INR). In the group of 55 INR < 5 patients, 31% had more than one INR determination > 5 during follow-up. Multivariate analysis identified four variables as independent predictors of over-anticoagulation: artificial heart valve, poor treatment compliance, addition of potentially interactive new drugs, and illness in the last month. The high-INR group patients had more bleeding episodes (21.8 vs 4.08%; p = 0.008), one of which was major.
The incidence of excessive oral anticoagulation in our outpatient population was similar to that reported in other studies. Patients with INR > 5 had more total bleeding complications, mostly minor. It is recommended to proceed carefully with oral anticoagulant therapy in patients with an artificial heart valve, suspected poor treatment compliance, addition of potentially interactive new drugs, and illness in the last month.
很少有研究试图调查心脏病患者的临床病程或确定导致过度抗凝的因素。
确定接受醋硝香豆素治疗的心脏病门诊患者过度抗凝的发生率,分析与过度抗凝相关的因素,并识别出血并发症。
这项为期7个月的前瞻性观察性研究纳入了连续接受醋硝香豆素抗凝治疗的门诊患者。他们在抗凝门诊就诊。55例过度抗凝患者的高国际标准化比值(INR)组至少有一次检测的INR>5。49例患者的对照组INR结果严格在治疗范围内。
512例患者共进行了3683次INR测定。77次检测的INR>5(高INR的总体发生率为2%)。在55例INR>5的患者组中,31%在随访期间有不止一次INR测定>5。多变量分析确定了四个变量为过度抗凝的独立预测因素:人工心脏瓣膜、治疗依从性差、添加可能相互作用的新药以及上个月患病。高INR组患者有更多的出血事件(21.8%对4.08%;p=0.008),其中一次为大出血。
我们门诊患者口服抗凝过度的发生率与其他研究报道的相似。INR>5的患者有更多的总出血并发症,大多为轻微出血。建议对于有人工心脏瓣膜、怀疑治疗依从性差、添加可能相互作用的新药以及上个月患病的患者,谨慎进行口服抗凝治疗。